Drugs / G-Pen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03439072 | Jan → Apr 2018 | hypoglycemia, type 1 diabetes mellitus | Xeris Pharmaceuticals | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-05-21 | Xeris Pharmaceuticals | Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting xerispharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G-Pen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03439072 ↗ |
| Route | Subcutaneous | “1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector” NCT03439072 ↗ |